Biogen Stock Tumbles After European Regulators Unexpectedly Reject Alzheimer’s Drug
Investor's Business DailyBiogen stock tumbled Friday after European regulators rejected its Eisai-partnered Alzheimer’s treatment, citing steep side effects.
The post Biogen Stock Tumbles After European Regulators Unexpectedly Reject Alzheimer's Drug appeared first on Inv…